CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT

INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor. With limited effective therapeutic strategies, prognosis for GBM is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRMT5) is upregulated in GBM; its inhibition promote...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Otani, Yoshihiro, Namagiri, Sriya, Thammegowda, Shilpa, Sur, Hannah, Chowdhury, Ashis, Lewis, Cole, Shimizu, Toshihiko, Lee, Tae Jin, Maric, Dragan, Yoo, Ji Young, Heiss, John, Kaur, Balveen, Banasavadi-Siddegowda, Yeshavanth Kumar
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Cell Signaling and Signaling Pathways
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650434/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.129
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados